Mike Pilato appointed President and CEO effective June 1, 2021 Jamieson Wellness Inc. announced today that the Company’s President and CEO Mark Hornick has decided to retire, after leading Jamieson Wellness through seven years of unprecedented growth. Jamieson Canada President Mike Pilato will advance to the role of President and CEO, effective June 1, 2021. “I am thankful to Mark for his skillful leadership ...

Mike Pilato appointed President and CEO effective June 1, 2021

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company's President and CEO Mark Hornick has decided to retire, after leading Jamieson Wellness through seven years of unprecedented growth. Jamieson Canada President Mike Pilato will advance to the role of President and CEO, effective June 1, 2021.

"I am thankful to Mark for his skillful leadership building our global presence and entrenching Jamieson as one of Canada's most trusted brands," said David Williams, Chair of the Board of Directors at Jamieson Wellness. "During his tenure, Mark restructured the organization behind a new vision, mission, and values, and with the support of a new leadership team, implemented a rapid growth strategy, doubling the company's topline revenue. The Board of Directors and I wish Mark the very best in his retirement and as we look to the future, we are confident that Mike is the right leader to take Jamieson to the next level."

"It has been my absolute honour to lead this company for the past seven years," said Mr. Hornick. "Our business has never been stronger, supported by a powerful brand, engaging culture and the deep commitment of our employees. The momentum we have driven over the past few years is still building, reinforcing that we have the right strategy in place to meet our long-term objectives. Mike is highly experienced with a proven track record of excellence and shared vision of improving the world's health and wellness. Over the next few months, Mike and I will work together to complete what has been an ongoing leadership transition."

"Jamieson Wellness is a highly respected global company with an amazing, dedicated team and an iconic brand that consumers around the world trust to support their health and wellness needs," said Mr. Pilato. "We have honed the company's long-term strategy over the past two years, prioritizing international growth opportunities, especially in China, along with fueling our organic growth in Canada. I am committed to building on this strategy and ensuring a seamless transition. I thank Mark and the Board of Directors for their support and confidence and look forward to working closely with the entire Jamieson team to continue driving sustainable growth and market leadership expansion."

Mr. Pilato joined Jamieson Wellness in 2018 as President of the Company's Specialty Brands division and was promoted to President, Jamieson Canada, in February 2020. Prior to Jamieson, Mr. Pilato held multiple leadership positions in the CPG space, culminating with serving as General Manager and President of The Clorox Company of Canada. During his tenure he led the organization to four years of record growth across multiple categories including household products, natural health and personal care.

About Jamieson Wellness Inc.

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions by Lorna Vanderhaeghe, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's future plans, goals, strategies, intentions, beliefs, objectives, economic performance or expectations. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 27, 2020 and under the "Risk Factors" section in the Company's MD&A filed February 25, 2021. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the Company's MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

Investor and Media Contact:
Ruth Winker
Jamieson Wellness
416-705-5437
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group (68/699) to 6.8% (48/709) in the molnupiravir group, for an absolute risk reduction of 3.0% (95% confidence interval [CI]: 0.1, 5.9; nominal p-value=0.0218) and a relative risk reduction of 30% (relative risk 0.70; 95% CI: 0.49, 0.99). Nine deaths were reported in the placebo group, and one in the molnupiravir group. The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211126005279/en/

Keep reading... Show less

Jamieson Wellness Inc. Announces Appointment of New Director

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL), announced today the appointment of Tania M. Clarke, Senior Vice-President and Chief Financial Officer of New Look Vision Group Inc., to the Company's Board of Directors.

"I am very pleased to welcome Ms. Clarke to our Board of Directors," said David Williams, Chairman of the Board. "Ms. Clarke's strong financial acumen coupled with her global consumer and retail experience will be invaluable as we continue to expand our reach to consumers around the world. Based in Montreal, Ms. Clarke will also provide more local perspective to support our continued growth in Canada and specifically the Quebec market."

Keep reading... Show less

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 5:10 p.m. Eastern Standard Time.

To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.

Keep reading... Show less

Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Frank Clyburn, executive vice president and president of Human Health, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021 at 10:30 a.m. ET.

Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentations at https://investors.merck.com/events-and-presentations/default.aspx .

Keep reading... Show less

Health Canada Approves KEYTRUDA® in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1

Conditional Approval Based on Data from Phase 3 KEYNOTE-355 Trial; Introduces First Breast Cancer Indication for KEYTRUDA ®

Merck (NYSE: MRK), known as MSD outside the United States and Canada today announced that Health Canada has granted conditional approval for KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) and who have not received prior chemotherapy for metastatic disease. 1 This conditional approval is based on the results of the pivotal Phase 3 KEYNOTE-355 trial which demonstrated KEYTRUDA ® 's ability to improve progression-free survival (PFS) in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabinecarboplatin), as compared to chemotherapy alone. 2

Keep reading... Show less
Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University

Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University

Love Pharma Inc. ("LOVE" and or the "Company") (CSE:LUV) (FSE:G1Q0), is pleased to announce that it has executed a Letter of Intent ("LOI") to acquire 100% of MicroDoz Therapy Inc. ("MicroDoz"), which has an exclusive partnership and license with a world leading university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder. Upon the closing of the definitive agreement, the Company expects to release the details of the program and university partner

This new partnership and development program will add to the Company's comprehensive portfolio of intellectual property and further validate the Company's effort to be a frontrunner in the psychedelics and therapeutics space.

Keep reading... Show less

Top News

Related News